Latest Bacteriophages Stories
WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration.
In a new study this week, Rice University scientists bring the latest tools of computational biology to bear in examining how the processes of natural selection and evolution influence the way bacteria acquire immunity from disease.
Viruses are well known for attacking humans and animals, but some viruses instead attack bacteria.
Research at the University of Leicester is focussing on a major killer in UK hospitals.
LONGMONT, Colo., Jan. 13 /PRNewswire/ -- A new bacterial identification test that rapidly identifies MRSA infections moved closer to market with conclusion of its first multicenter clinical trial, which was announced today by MicroPhage, Inc., http://www.microphage.com.
U.S. university researchers say they've uncovered clues from a virus quirk that may lead to new ways to kill E.
Dyax Corp. (NASDAQ: DYAX) announced today that it has entered into a $50 million loan agreement with Cowen Healthcare Royalty Partners, L.P. ("CHRP") secured by the Company's phage display Licensing and Funded Research Program ("LFRP").
OmniLytics, Inc. today announced the issuance of a no objection letter from the USDA's Food Safety and Inspection Service (FSIS) for use of Salmonella targeted bacteriophages from OmniLytics, Inc. applied to poultry.
Dyax Corp. (NASDAQ: DYAX) and AVEO Pharmaceuticals, Inc. announced today that Dyax has granted AVEO a non-exclusive license to Dyax's proprietary antibody phage display libraries for the discovery and development of therapeutic antibodies.
The human antibody company, Affitech AS, announced today that it has further strengthened its intellectual property (IP) position in the human antibody discovery area through a series of IP cross-licensing and in-licensing deals.
Klebsiella pneumoniae is a Gram-negative, non-motile, encapsulated, lactose fermenting, facultative anaerobic, rod shaped bacterium found in the normal flora of the mouth, skin, and intestines. It is the most important member of the Klebsiella genus of Enterobacteriaceae. It is naturally occurring in soil and about 30% of strains can fix nitrogen in anaerobic conditions. Hans Christian Gram developed the technique now known as Gram staining in 1884 to discriminate between K. pneumoniae and...
- A trick or prank.